Clinical trial
A Phase 1 Study of SGN-CD48A in Patients With Relapsed or Refractory Multiple Myeloma
NCT03379584 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Study of SGN-CD48A in Patients With Relapsed or Refractory Multiple Myeloma
- Lead sponsor
- Seagen Inc.
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- February 20, 2018
- Completion date
- August 23, 2019
- Enrollment
- 14 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.